@article {Rowe58, author = {Steven P. Rowe and Scott P. Campbell and Margarita Mana-Ay and Zsolt Szabo and Mohamad E. Allaf and Kenneth J. Pienta and Martin G. Pomper and Ashley E. Ross and Michael A. Gorin}, title = {Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer}, volume = {61}, number = {1}, pages = {58--61}, year = {2020}, doi = {10.2967/jnumed.119.226514}, publisher = {Society of Nuclear Medicine}, abstract = {Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen{\textendash}targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7\%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1\% of patients with a PSA level of less than 1.0 ng/mL and in 88.9\% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5{\textendash}57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen{\textendash}targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/61/1/58}, eprint = {https://jnm.snmjournals.org/content/61/1/58.full.pdf}, journal = {Journal of Nuclear Medicine} }